MirZyme Therapeutics and Archerfish Precision Diagnostics Announce Strategic Collaboration to Advance Maternal Health Innovation in Southeast Asia.
- MirZyme Team
- May 22
- 3 min read
Every life saved begins with early detection. MPREG® empowers timely intervention—because no baby should be lost to preeclampsia.
MirZyme Therapeutics Limited, a pioneering biotech company bringing the world’s first precision diagnostic to obstetrics, and Archerfish Precision Diagnostics Pte Limited, a leading Singapore-based diagnostics innovator, today announced the signing of a Memorandum of Understanding (MoU) to collaborate on the commercialisation, clinical validation, and regional promotion of MirZyme’s Risk Evaluation Genie (M-PREG®) diagnostic platform across Singapore and Southeast Asia. A unique collaboration will bridge scientific innovation from the UK with health system access in Asia to combat preeclampsia.
Preeclampsia is often called a “silent killer” because it can strike without warning and is traditionally detected using crude markers like blood pressure and urine protein—methods that miss many cases. Globally, the condition claims the lives of over 80,000 women and 500,000 babies every year, with the burden heaviest in low-resource and emerging healthcare systems. It effects rich countries too where likelihood of dying in pregnancy has subsided.
Women who survive preeclampsia face long-term risks: a 4x higher likelihood of developing heart disease, and 2x increased risk of both stroke and dementia later in life. Preeclampsia is increasingly understood not just as a pregnancy complication—but as an early warning signal of future chronic vascular disease. The long-term cost to healthcare systems runs into the billions, making early prediction a public health and economic imperative.
M-PREG® changes this landscape. M-PREG® is now UKCA approved and available for clinical use in the UK—a major regulatory milestone that demonstrates MirZyme’s ability to deliver global health impact with lean resources. This digital diagnostic applies unique algorithms to existing blood-based biomarkers to identify pregnant women at risk of preeclampsia—enabling timely interventions that can save both mother and baby. As a noninvasive, blood-test-based digital platform, it leverages a powerful algorithm to deliver risk assessment with precision—requiring no new hardware and minimal training. This makes it ideally suited for widespread adoption across Southeast Asia’s diverse healthcare environments.
The collaboration will focus on accelerating access to M-PREG® in Malaysia, Indonesia, Thailand, and Vietnam— countries where maternal health disparities remain acute. Under the terms of the MoU, MirZyme will provide the diagnostic platform, algorithm updates, and training, while Archerfish will lead local regulatory approvals, clinical validation, and commercial distribution. The partnership will also include joint marketing, brand alignment, and a shared mission to improve maternal and neonatal outcomes.
Professor Asif Ahmed, CEO & Executive Chairman of MirZyme Therapeutics, commented: “This collaboration marks a pivotal step toward realising our vision: One Test, One Pill, Save Two Lives. By combining MirZyme’s science with Archerfish’s regional expertise, we aim to ensure that no woman—whether in Birmingham or Bangkok—dies from preeclampsia. This is not just about saving lives today, but also about preventing chronic disease in the decades that follow.”
Dr Lim Cheok Peng, Chairman of Archerfish Precision Diagnostics, added: “We are excited to join forces with MirZyme in this vital initiative. M-PREG® represents a breakthrough in maternal health diagnostics, and we look forward to working closely to secure regulatory approval in our region and make this important tool available to healthcare systems across Southeast Asia. Our mission at Archerfish is to advance precision diagnostics, and this collaboration perfectly aligns with that goal.”
The MoU reflects both companies’ shared commitment to reducing health inequalities and advancing maternal and neonatal health through scientific innovation. The parties will also explore potential funding opportunities and avenues for Archerfish to invest in MirZyme to further strengthen the collaboration.
Professor Pensée Wu MBChB MD(Res) FRCOG, Professor of Obstetrics at Keele University and Consultant at University Hospitals of North Midlands NHS Trust, commented: “M-PREG® has the potential to transform the clinical management of preeclampsia. Its ability to deliver rapid, evidence-based risk stratification through a simple blood test gives clinicians the confidence to make earlier, informed decisions—improving outcomes for both mothers and babies.”
About MirZyme Therapeutics Limited
MirZyme Therapeutics is a UK-based, U.S. ARPA-H selected biotech company set to transform maternal health. The dual platform addresses preeclampsia—a leading cause of maternal and neonatal mortality—through an approved diagnostic (M-PREG®) and a first-inclass oral therapeutic (MZe786). With a mission of “One Test, One Pill, Save Two Lives,” MirZyme’s groundbreaking solutions aim to transform pregnancy care globally.
About Archerfish Precision Diagnostics Pte Limited
Archerfish Precision Diagnostics is a Singapore-based company committed to advancing medical diagnostics through precision technology and innovation. Focused on improving patient outcomes, Archerfish develops and delivers cutting-edge diagnostic solutions to meet the needs of evolving healthcare systems.
Media Contact for MirZyme Therapeutics:
Shahzad Khan
Commercial Director
+447447 046763
Media Contact for Archerfish Precision Diagnostics:
Angeline Wong
Senior Manager, Strategic Development
+65 9090 5380
Commentaires